NCT07012538Completed
RASi for Preventing Postoperative Recurrence of Stage II/III Colon Cancer
Renin-angiotensin System Inhibitor for Preventing Postoperative Recurrence of Stage II/III Colon Cancer
Source: ClinicalTrials.gov · Last updated 10 Jun 2025
Brief summary (registry, in English)
The goal of this retrospective cohort study is to learn about the long-term effects of renin-angiotensin system inhibitors (RASi) in preventing patients with hypertension and stage II/III colon cancer from recurrence and metastases after radical resection. The main question it aims to answer is: Does RASi improve the 3-year disease-free survival of patients with hypertension and stage II/III colon cancer after surgery? Participants with hypertension and already having radical resection of stage II/III colon cancer will be followed up for 3 years.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 2640 (actual)
- First submitted
- 30 May 2025
- Start date
- 4 Jan 2012
- Primary completion date
- 30 Dec 2021
- Lead sponsor
- Fudan University
- Diseases
- Colorectal cancer
- NCT number
- NCT07012538
What you commit to
- Study type: Observational
- Participants enrolled: 2640
- From 4 Jan 2012 to the primary completion date, 30 Dec 2021
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received any of preoperative anti-cancer treatment.
Other illness
- Emergency surgery for acute intestinal obstruction, bleeding, perforation, etc;
- Multiple primary colorectal cancer;
- Hereditary colorectal cancer (familial adenomatosis polyposis, Lynch Syndrome, etc.);
- Co-existent inflammatory bowel disease;
Other
- Pregnancy or lactation;
Who the study is looking for
- Inferior tumor edge \> 15 cm from anal verge;
- Received radical resection of primary tumor;
- Pathological proved stage II or stage III adenocarcinoma;
- No evidence of distant metastases at time of surgery (including pelvis, peritoneum, liver, lung, brain, bone, distant lymph node, etc), according to ultrasound, CT, MRI, PET-CT, intraoperative exploration, etc;
- Combined with hypertension at time of surgery;
- No other malignancies in medical history except adequately treated basocellular carcinoma of the skin or in situ carcinoma of the cervix uteri;
- Informed consent.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhongshan Hospital,Fudan University Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.